Moderna Co-Founder Kenneth Chien’s New Biotech Secures $950M RNA Deal with Etherna
Kenneth Chien's New Venture:
Kenneth Chien, a co-founder of Moderna, has launched a new biotech company that has inked a $950M RNA deal with Etherna3.
Background:
Chien is a renowned medical scientist with expertise in cardiovascular science and regenerative medicine. He has been a research director at Karolinska Institute since 2013 and has co-founded several biotech companies, including Moderna Therapeutics12.
mRNA Therapies:
Chien's research has focused on using mRNA for therapeutic applications, particularly in cardiovascular medicine. His work has led to significant advancements in mRNA technology, including the development of mRNA therapies for heart disease12.
Recent Developments:
Chien has recently left his professorship at Karolinska Institute to focus on developing new mRNA therapies in the biotechnology industry. His new company aims to unlock the full potential of mRNA technology for various diseases2.
Collaborations:
Chien has collaborated with AstraZeneca and other pharmaceutical companies to advance mRNA therapies. His research has reached clinical trials, demonstrating the potential of mRNA to regenerate heart tissue and improve blood flow12.
Investments:
Chien has also invested in other mRNA startups, such as eTheRNA, a Belgian-based company developing mRNA therapies. He joined the company's board and helped finance a 39 million euro series B2 round45.
Sources:
1. https://en.wikipedia.org/wiki/KennethR.Chien
2. https://news.ki.se/innovation-occurs-at-the-intersection-of-different-worlds
4. https://www.fiercebiotech.com/biotech/moderna-co-founder-helps-finance-latest-series-b-belgian-mrna-shop
5. https://www.globenewswire.com/news-release/2022/08/23/2502927/0/en/mRNA-Leading-Expert-Kenneth-Chien-and-Novalis-LifeSciences-Marijn-Dekkers-Investing-EUR-39M-Series-B2-Financing-in-mRNA-Technology-Platform-Company-eTheRNA.html